COMPOUND 65 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Compound 65, and what generic alternatives are available?
Compound 65 is a drug marketed by Alra and is included in one NDA.
The generic ingredient in COMPOUND 65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
Summary for COMPOUND 65
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 1,650 |
Patent Applications: | 2 |
Formulation / Manufacturing: | see details |
DailyMed Link: | COMPOUND 65 at DailyMed |
Recent Clinical Trials for COMPOUND 65
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aphios | Phase 2 |
Kevin Winthrop | Phase 2 |
National Jewish Health | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for COMPOUND 65
US Patents and Regulatory Information for COMPOUND 65
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alra | COMPOUND 65 | aspirin; caffeine; propoxyphene hydrochloride | CAPSULE;ORAL | 084553-002 | Aug 17, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |